Atkore has seen a 21% run-up since we initiated BUY coverage on the stock in March 2023. Atkore’s valuation is still reasonable and there is still some upside. Our longer-term thesis remains intact.

We maintain our fair value estimate of HKD 64 for JD Health 06618 after the company reported second-half revenue of CNY 26.5 billion, which was better than the top range of guidance of CNY 23.9 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...